Ask AI
ProCE Banner Activity

Updates on New Treatment Options in Relapsed/Refractory Myeloma

Slideset

These downloadable slides highlight new treatment options including CAR T-cell therapies, bispecific antibodies, and combination therapies for the management of relapsed/refractory multiple myeloma based on the most recent clinical trial data and expert guidelines.

Released: December 05, 2025

Share

Provided by

Provided by the National Comprehensive Cancer Network (NCCN) in collaboration with Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by independent medical education grants from AbbVie and GSK.
Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Supported by a medical education grant from Karyopharm Therapeutics.

AbbVie

GSK

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics

Partners

Clinical Care Options, LLC

ProCE Banner

Target Audience

This educational activity is intended for hematologists, medical oncologists, physician associates, nurses, pharmacists, and other healthcare professionals who care for patients with multiple myeloma. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Assess risk of developing multiple myeloma in patients with smoldering myeloma based the latest definitions from IWMG

  • Plan individualized treatment strategies for patients with smoldering myeloma through consideration of the available clinical data, NCCN Guidelines, comorbidities, and patient age/fitness and preferences 

  • Develop individualized treatment strategies for patients with newly diagnosed multiple myeloma through consideration of the available clinical data as well as NCCN Guidelines, risk assessment, comorbidities, and patient age/fitness and preferences

  • Select optimal therapies for patients with relapsed/refractory multiple myeloma based on individual patient and disease characteristics, NCCN Guideline recommendations, and response to and tolerance of previous therapies

  • Identify patients with smoldering, newly diagnosed, or relapsed/refractory multiple myeloma who would be eligible for enrollment on key ongoing clinical trials

  • Appraise the efficacy and safety evidence of novel therapeutics and emerging combination regimens for patients with multiple myeloma